Personalis Shares Are Trading Higher After the Company and Moderna Recently Announced a Multi-year Extension to Continue Utilizing the Personalis ImmunoID NeXT Platform and Technology for V940/mRNA-4157. The Company Also Announced an Investment From...
Personalis Shares Are Trading Higher After the Company and Moderna Recently Announced a Multi-year Extension to Continue Utilizing the Personalis ImmunoID NeXT Platform and Technology for V940/mRNA-4157. The Company Also Announced an Investment From...
Personalis的股票在公司与Moderna最近宣布继续使用Personalis ImmunoID NeXt平台和科技用于V940/mRNA-4157的多年扩展后开始上涨。公司还宣布了一项投资来自...
Personalis Shares Are Trading Higher After the Company and Moderna Recently Announced a Multi-year Extension to Continue Utilizing the Personalis ImmunoID NeXT Platform and Technology for V940/mRNA-4157. The Company Also Announced an Investment From Merck.
Personalis的股价走高，此前该公司和Moderna最近宣布将Personalis Immunoid NeXT平台和技术延期多年，继续使用V940/mrna-4157的Personalis Immunoid NeXT平台和技术。该公司还宣布了默沙东的投资。
资讯热榜
更新时间